Exicure, Inc. (NASDAQ:XCUR) Sees Large Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCUR) saw a significant drop in short interest in May. As of May 15th, there was short interest totaling 32,290 shares, a drop of 38.4% from the April 30th total of 52,380 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average trading volume of 13,641 shares, the short-interest ratio is presently 2.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Exicure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Exicure Trading Down 6.6%

NASDAQ:XCUR opened at $3.11 on Wednesday. Exicure has a 12 month low of $2.63 and a 12 month high of $10.80. The company has a market cap of $19.81 million, a PE ratio of -2.01 and a beta of 3.53. The company has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $4.41.

Exicure (NASDAQ:XCUR) last posted its earnings results on Friday, May 29th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.31.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.